Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + capecitabine
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Anlotinib + capecitabine is a combination therapy consisting of anlotinib, a multi-target tyrosine kinase inhibitor, and capecitabine, an oral fluoropyrimidine chemotherapy agent. This combination has been studied primarily for metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC). The regimen has shown promising efficacy in clinical trials, particularly as first-line therapy or maintenance therapy for RAS/BRAF wild-type mCRC. The combination offers the advantage of being a completely oral maintenance strategy, which may increase compliance and convenience for patients.
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR-1 (Vascular endothelial growth factor receptor 1)FGFR (FGFR family)RET (Rearranged during transfection receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on anlotinib + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + capecitabine.